Medtronic PLC (NYSE:MDT) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Medtronic PLC (NYSE:MDT) have been assigned an average rating of “Moderate Buy” from the twenty-seven brokerages that are presently covering the firm, Marketbeat Ratings reports. Nine analysts have rated the stock with a hold recommendation and eighteen have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $99.3750.

Several equities analysts recently weighed in on MDT shares. Evercore set a $105.00 target price on Medtronic in a research report on Monday, July 6th. Deutsche Bank Aktiengesellschaft reduced their price target on Medtronic from $100.00 to $78.00 and set a “hold” rating for the company in a research report on Thursday, June 4th. TD Cowen lowered their price objective on Medtronic from $119.00 to $100.00 and set a “buy” rating on the stock in a research report on Friday, July 10th. BTIG Research reiterated a “buy” rating and set a $91.00 price objective on shares of Medtronic in a research note on Tuesday, August 18th. Finally, Needham & Company LLC increased their target price on shares of Medtronic from $101.00 to $114.00 and gave the stock a “buy” rating in a report on Thursday.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Needham raised its price target to $114 from $101 and reiterated a Buy rating, implying substantial upside from recent trading levels. The firm expects Medtronic to beat first-quarter estimates and raise its fiscal 2027 guidance, potentially providing a near-term catalyst. Medtronic price target raised by Needham
• Positive Sentiment: Analysts expect continued growth across Medtronic’s Cardiovascular, Neuroscience and Diabetes businesses. Cardiovascular performance and expanding renal-denervation activity are highlighted as important growth opportunities. Medtronic Q1 estimates and guidance
• Positive Sentiment: Medtronic reaffirmed its dividend trajectory, approving a $0.72-per-share fiscal 2027 second-quarter dividend. The ongoing dividend supports the stock’s appeal to income-oriented investors. Medtronic dividend update
• Positive Sentiment: Recent coverage points to strengthening device momentum and a potential rebound, while Medtronic remains viewed as a relatively inexpensive, diversified alternative to faster-growing surgical-robotics companies. Medtronic device momentum

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the sale, the executive vice president directly owned 37,227 shares of the company’s stock, valued at $2,994,539.88. This represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.27% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Anfield Capital Management LLC raised its holdings in Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 230 shares during the period. Monetary Solutions Ltd bought a new position in shares of Medtronic in the fourth quarter worth about $27,000. Acumen Wealth Advisors LLC bought a new position in shares of Medtronic in the fourth quarter worth about $29,000. IAG Wealth Partners LLC purchased a new stake in shares of Medtronic during the second quarter worth about $30,000. Finally, Imprint Wealth LLC purchased a new stake in shares of Medtronic during the third quarter worth about $31,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Stock Down 2.2%

MDT opened at $90.04 on Friday. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52. Medtronic has a 1-year low of $73.31 and a 1-year high of $106.33. The company has a market capitalization of $115.24 billion, a PE ratio of 24.14, a PEG ratio of 2.47 and a beta of 0.55. The firm’s 50 day simple moving average is $85.34 and its two-hundred day simple moving average is $85.63.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. The firm had revenue of $9.81 billion during the quarter, compared to the consensus estimate of $9.62 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.62 EPS. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, equities analysts forecast that Medtronic will post 5.94 EPS for the current year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be given a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date is Friday, September 25th. Medtronic’s dividend payout ratio is presently 77.21%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).